Understanding neuromodulatory effects of serotonin 2A receptor (5-HT2AR) agonists with diverse pharmacological profiles is relevant to advancing psychedelic-related drug applications. We performed simultaneous positron emission tomography (PET) and pharmacological magnetic resonance imaging (phMRI) in anesthetized nonhuman primates (NHP; N = 3) to examine partial agonists with varying 5-HT2AR affinities and selectivity profiles: psilocybin (30, 60, and 90 µg/kg), lisuride (5 µg/kg), and 25CN-NBOH (15 µg/kg). Receptor occupancy was assessed with [11C]MDL-100907 PET, and cerebral blood volume (CBV) changes were measured with phMRI. Mixed partial agonists psilocybin and lisuride evoked biphasic CBV responses, whereas the selective 25CN-NBOH produced monophasic CBV increases. Cortical occupancy for psilocybin plateaued at 60 µg/kg (32%), whereas a lower dose of lisuride (5 µg/kg) resulted in similar occupancy (31%). Administration of 25CN-NBOH resulted in lower occupancy (7%) but larger changes in CBV compared to psilocybin and lisuride. The associations between CBV and 5-HT2AR occupancy appear linear for lisuride and 25CN-NBOH, but not for psilocybin. We speculate that the temporal and spatial differences in hemodynamic responses of the three agonists could stem from mixed affinity profiles. This work provides an understanding of pharmacological impacts of mixed serotonergic agonists being pursued as therapeutics for psychiatric conditions, offering valuable insights for future drug applications and development strategies.
KredietEBostoenTBreeksemaJ, et al.
Reviewing the potential of psychedelics for the treatment of PTSD. Int J Neuropsychopharmacol2020;
23: 385–400.
2.
ReiffCMRichmanEENemeroffCB, et al.
Psychedelics and psychedelic-assisted psychotherapy. Am J Psychiatry2020;
177: 391–410.
3.
López-GiménezJFGonzález-MaesoJ.Hallucinogens and serotonin 5-HT2A receptor-mediated signaling pathways. Curr Top Behav Neurosci2018;
36: 45–73.
4.
MatthewsPMRabinerEAPasschierJ, et al.
Positron emission tomography molecular imaging for drug development. Br J Clin Pharmacol2012;
73: 175–186.
5.
JenkinsBG.Pharmacologic magnetic resonance imaging (phMRI): imaging drug action in the brain. Neuroimage2012;
62: 1072–1085.
6.
HansenHDMandevilleJBSanderCY, et al.
Functional characterization of 5-HT1B receptor drugs in non-human primates using simultaneous PET-MR. J Neurosci2017;
37: 10671–10678.
7.
DarmonMAl AwabdhSEmeritMB, et al.
Insights into serotonin receptor trafficking: cell membrane targeting and internalization. Prog Mol Biol Transl Sci2015;
132: 97–126.
8.
RothBLGrayJA.Paradoxical trafficking and regulation of 5-HT(2A) receptors by agonists and antagonists. Brain Res Bull2001;
56: 441–451.
9.
JensenAAMcCorvyJDLeth-PetersenS, et al.
Detailed characterization of the In vitro pharmacological and pharmacokinetic properties of N-(2-Hydroxybenzyl)-2, 5-Dimethoxy-4-Cyanophenylethylamine (25CN-NBOH), a highly selective and brain-penetrant 5-HT2A receptor agonist. J Pharmacol Exp Ther2017;
361: 441–453.
10.
Carhart-HarrisRLLeechRErritzoeD, et al.
Functional connectivity measures after psilocybin inform a novel hypothesis of early psychosis. Schizophr Bull2013;
39: 1343–1351.
11.
Carhart-HarrisRLMuthukumaraswamySRosemanL, et al.
Neural correlates of the LSD experience revealed by multimodal neuroimaging. Proc Natl Acad Sci U S A2016;
113: 4853–4858.
12.
SanderCYKeilBChondeDB, et al.
A 31-Channel MR brain array coil compatible with positron emission tomography. Magn Reson Med2015;
73: 2363–2375.
13.
LuHPatelSLuoF, et al.
Spatial correlations of laminar BOLD and CBV responses to rat whisker stimulation with neuronal activity localized by fos expression. Magn Reson Med2004;
52: 1060–1068.
14.
MandevilleJBMarotaJJKosofskyBE, et al.
Dynamic functional imaging of relative cerebral blood volume during rat forepaw stimulation. Magn Reson Med1998;
39: 615–624.
15.
SledJGZijdenbosAPEvansAC.A nonparametric method for automatic correction of intensity nonuniformity in MRI data. IEEE Trans Med Imaging1998;
17: 87–97.
CoxRW.AFNI: software for analysis and visualization of functional magnetic resonance neuroimages. Comput Biomed Res1996;
29: 162–173.
18.
JenkinsonMBannisterPBradyM, et al.
Improved optimization for the robust and accurate linear registration and motion correction of brain images. Neuroimage2002;
17: 825–841.
19.
RohlfingTKroenkeCDSullivanEV, et al.
The INIA19 template and NeuroMaps atlas for primate brain image parcellation and spatial normalization. Front Neuroinform2012;
6: 27.
MandevilleJB.IRON fMRI measurements of CBV and implications for BOLD signal. Neuroimage2012;
62: 1000–1008.
22.
IchiseMLiowJ-SLuJ-Q, et al.
Linearized reference tissue parametric imaging methods: application to [11C]DASB positron emission tomography studies of the serotonin transporter in human brain. J Cereb Blood Flow Metab2003;
23: 1096–1112.
23.
TalbotPSSlifsteinMHwangD-R, et al.
Extended characterisation of the serotonin 2A (5-HT 2A) receptor-selective PET radiotracer 11C-MDL100907 in humans: quantitative analysis, test-retest reproducibility, and vulnerability to endogenous 5-HT tone. Neuroimage2012;
59: 271–285.
24.
FischmanAJ, et al.
Positron emission tomographic analysis of central 5-hydroxytryptamine2 receptor occupancy in healthy volunteers treated with the novel antipsychotic agent, ziprasidone. Journal of Pharmacology and Experimental Therapeutics1996;
279: 939–947.
25.
ChowTWMamoDCUchidaH, et al.
Test-retest variability of high resolution positron emission tomography (PET) imaging of cortical serotonin (5HT2A) receptors in older, healthy adults. BMC Med Imaging2009;
9: 12.
26.
MadsenMKStenbækDSArvidssonA, et al.
Psilocybin-induced changes in brain network integrity and segregation correlate with plasma psilocin level and psychedelic experience. Eur Neuropsychopharmacol2021;
50: 121–132.
27.
BarrettFSZhouYCarbonaroTM, et al.
Human cortical serotonin 2A receptor occupancy by psilocybin measured using [11C]MDL 100,907 dynamic PET and a resting-state fMRI-based brain parcellation. Front Neuroergon2021;
2: 784576.
28.
Palhano-FontesFAndradeKCTofoliLF, et al.
The psychedelic state induced by ayahuasca modulates the activity and connectivity of the default mode network. PLoS One2015;
10: e0118143.
29.
HaslerFBourquinDBrenneisenR, et al.
Determination of psilocin and 4-hydroxyindole-3-acetic acid in plasma by HPLC-ECD and pharmacokinetic profiles of oral and intravenous psilocybin in man. Pharm Acta Helv1997;
72: 175–184.
30.
DonovanLLJohansenJVRosNF, et al.
Effects of a single dose of psilocybin on behaviour, brain 5-HT2A receptor occupancy and gene expression in the pig. Eur Neuropsychopharmacol2021;
42: 1–11.
31.
FinnemaSJStepanovVEttrupA, et al.
Characterization of [(11)C]cimbi-36 as an agonist PET radioligand for the 5-HT(2A) and 5-HT(2C) receptors in the nonhuman primate brain. Neuroimage2014;
84: 342–353.
32.
TurtonSNuttDJCarhart-HarrisRL.A qualitative report on the subjective experience of intravenous psilocybin administered in an fMRI environment. Curr Drug Abuse Rev2014;
7
33.
MadsenMKFisherPMBurmesterD, et al.
Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels. Neuropsychopharmacology2019;
44: 1328–1334.
34.
MandevilleJBSanderCYMJenkinsBG, et al.
A receptor-based model for dopamine-induced fMRI signal. Neuroimage2013;
75: 46–57.
35.
PuigMVArtigasFCeladaP.Modulation of the activity of pyramidal neurons in rat prefrontal cortex by raphe stimulation in vivo: involvement of serotonin and GABA. Cereb Cortex2005;
15: 1–14.
36.
MoonHSJiangHVoTT, et al.
Contribution of excitatory and inhibitory neuronal activity to BOLD fMRI. Cereb Cortex2021;
31: 4053–4067.
37.
AghajanianGKMarekGJ.Serotonin induces excitatory postsynaptic potentials in apical dendrites of neocortical pyramidal cells. Neuropharmacology1997;
36: 589–599.
38.
AghajanianGKMarekGJ.Serotonin, via 5-HT(2A) receptors, increases EPSCs in layer V pyramidal cells of prefrontal cortex by an asynchronous mode of glutamate release. Brain Res1999;
825
39.
JakabRLGoldman-RakicPS.Segregation of serotonin 5-HT2A and 5-HT3 receptors in inhibitory circuits of the primate cerebral cortex. Journal of Comparative Neurology2000;
417
40.
Carhart-HarrisRLNuttDJ.Serotonin and brain function: a tale of two receptors. J Psychopharmacol2017;
31: 1091–1120. Preprint at https://doi.org/10.1177/0269881117725915
41.
LiuJWangYXiaK, et al.
Acute psilocybin increased cortical activities in rats. Front Neurosci2023;
17: 1168911.
42.
ShaharOBotvinnikAEsh-ZuntzN, et al.
Role of 5-HT2A, 5-HT2C, 5-HT1A and TAAR1 receptors in the head twitch response induced by 5-hydroxytryptophan and psilocybin: translational implications. Int J Mol Sci2022;
23
43.
SanderCYHookerJMCatanaC, et al.
Imaging agonist-induced D2/D3 receptor desensitization and internalization in vivo with PET/fMRI. Neuropsychopharmacology2016;
41: 1427–1436.
44.
SanderCYHookerJMCatanaC, et al.
Neurovascular coupling to D2/D3 dopamine receptor occupancy using simultaneous PET/functional MRI. Proc Natl Acad Sci U S A2013;
110: 11169–11174.
45.
Marona-LewickaDThistedRANicholsDE.Distinct temporal phases in the behavioral pharmacology of LSD: dopamine D2 receptor-mediated effects in the rat and implications for psychosis. Psychopharmacology (Berl)2005;
180: 427–435.
46.
Borroto-EscuelaDORomero-FernandezWNarvaezM, et al.
Hallucinogenic 5-HT2AR agonists LSD and DOI enhance dopamine D2R protomer recognition and signaling of D2-5-HT2A heteroreceptor complexes. Biochem Biophys Res Commun2014;
443: 278–284.
47.
LawnTDipasqualeOVamvakasA, et al.
Differential contributions of serotonergic and dopaminergic functional connectivity to the phenomenology of LSD. Psychopharmacology (Berl)2022;
239: 1797–1808.
48.
JensenAAHalberstadtALMärcher-RørstedE, et al.
The selective 5-HT2A receptor agonist 25CN-NBOH: structure-activity relationship, in vivo pharmacology, and in vitro and ex vivo binding characteristics of [3H]25CN-NBOH. Biochem Pharmacol2020;
177: 113979.
49.
WeyH-YPhillipsKAMcKayDR, et al.
Multi-region hemispheric specialization differentiates human from nonhuman primate brain function. Brain Struct Funct2014;
219: 2187–2194.
50.
KapurSSeemanP.NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D2 and serotonin 5-HT2 receptors – implications for models of schizophrenia. Mol Psychiatry2002;
7: 837–844.
51.
LinHKimJGParkSW, et al.
Enhancement of 5-HT2A receptor function and blockade of Kv1.5 by MK801 and ketamine: implications for PCP derivative-induced disease models. Exp Mol Med2018;
50: 1–8.
52.
MatsunagaFGaoLHuangX-P, et al.
Molecular interactions between general anesthetics and the 5HT2B receptor. J Biomol Struct Dyn2015;
33: 211–218.
53.
SandiegoCMJinXMulnixT, et al.
Awake nonhuman primate brain PET imaging with minimal head restraint: evaluation of GABAA-benzodiazepine binding with 11C-Flumazenil in awake and anesthetized animals. J Nucl Med2013;
54: 1962–1968.
54.
Carhart-HarrisRLErritzoeDWilliamsT, et al.
Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proc Natl Acad Sci U S A2012;
109: 2138–2143.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
